LGG-58. A PHASE II TRIAL OF POLY-ICLC IN THE MANAGEMENT OF RECURRENT OR PROGRESSIVE PEDIATRIC LOW GRADE GLIOMAS (NCT01188096): PRELIMINARY ANALYSIS

ABSTRACT: Abstract Low dose Poly-ICLC (Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose) has a direct immune enhancing action independent of interferon, including increased antibody response to antigen, and NK cell, T-cell, macrophage and cytokine activation.

METHODS

We conducted an immunotherapy trial to evaluate the effect of Poly-ICLC in the children with recurrent or progressive low grade gliomas. Criteria for enrollment: progression by MRI and or visual deterioration. Patients received Poly-ICLC 20mcg/kg/dose IM injection twice a week for up to 24 months.

RESULTS

23 patients enrolled, 22 evaluable. Ages 2-20 years. Ten females and 13 males Location: suprasellar (11), spine (1), disseminated (4), others (7). Six patients with NF-1. Pathology

SUBMITTER: Aguilera D 

PROVIDER: S-EPMC6012063 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature